|
Synonyms: JS-001 | JS001 | Loqtorzi® | toripalimab-tpzi
toripalimab is an approved drug (FDA (2023), EMA (2024))
Compound class:
Antibody
Comment: Toripalimab (JS001) is an anti-programmed cell death protein-1 (PD-1) immuno-oncology biologic [3]. It blocks the inhibitory immune checkpoint interaction between PD-1 and its ligands and reinstates a cytotoxic T cell response against tumour cells.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. FDA (2023) | China NMPA (2024) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10820 | toripalimab |
| Synonyms |
| JS-001 | JS001 | Loqtorzi® | toripalimab-tpzi |
| Database Links |
|
| GtoPdb PubChem SID | 485206110 |
| Search PubMed clinical trials | toripalimab |
| Search PubMed titles | toripalimab |
| Search PubMed titles/abstracts | toripalimab |
